Cumberland Pharmaceuticals Inc. (CPIX) News
Filter CPIX News Items
CPIX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest CPIX News From Around the Web
Below are the latest news stories about CUMBERLAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPIX as an investment opportunity.
3 Promising Penny Stocks With Market Caps Under $2B In USAs U.S. markets experience a slight pullback with the S&P 500 and Nasdaq Composite shedding some recent gains, investors are closely watching for opportunities amid fluctuating indices. For those looking to invest in smaller or newer companies, penny stocks—despite the name's vintage feel—can still offer surprising value. These stocks, often overlooked, can present compelling opportunities when backed by strong financials and growth potential, making them attractive options for investors... |
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing ChangeFDA approval of Acetadote's simplified dosing propels Cumberland Pharmaceuticals' stock to a 90% single-day surge |
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen. Acetaminophen, a common over-the-counter pain reliever and fever reducer, is the leading cause of acute liver failure in the United States. Eac |
Sector Update: Health Care Stocks Steady Pre-Bell TuesdayHealth care stocks were steady premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV) |
FDA APPROVES ACETADOTE® sNDACumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1. |
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)Cumberland Pharmaceuticals ( NASDAQ:CPIX ) Third Quarter 2024 Results Key Financial Results Revenue: US$9.09m (down... |
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...Despite weather-related disruptions and product challenges, CPIX reports strong revenue growth and strategic international expansions. |
Cumberland: Q3 Earnings SnapshotCPIX) on Thursday reported a loss of $1.5 million in its third quarter. The Nashville, Tennessee-based company said it had a loss of 11 cents per share. Losses, adjusted for non-recurring costs and stock option expense, were 2 cents per share. |
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company UpdateCumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity. |
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficac |